143 related articles for article (PubMed ID: 37881484)
1. Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report.
Wan Y; Zhu H
Front Oncol; 2023; 13():1256137. PubMed ID: 37881484
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Huang J; Guo Y; Huang W; Hong X; Quan Y; Lin L; Zhou J; Liang L; Zhang Y; Zhou J; Cai M; Zhu K
J Hepatocell Carcinoma; 2022; 9():157-170. PubMed ID: 35300208
[TBL] [Abstract][Full Text] [Related]
3. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient.
Zhang EL; Zhang ZY; Li J; Huang ZY
Onco Targets Ther; 2020; 13():12477-12487. PubMed ID: 33311988
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
Xu B; Lu D; Liu K; Lv W; Xiao J; Zhang X; Zhang Z; Chai J; Wang L
Drug Des Devel Ther; 2023; 17():507-518. PubMed ID: 36814894
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
7. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for patients with progression of advanced hepatocellular carcinoma after treatment with atezolizumab plus bevacizumab: a case series.
Kang W; Fu H; Luo Y; Noreika DM; Cong T; Li H; Yang Z
J Gastrointest Oncol; 2024 Apr; 15(2):780-787. PubMed ID: 38756648
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis.
Zhao Y; Liu W; Zheng L; Goyal S; Awosika J; Wang H; Yang S
J Gastrointest Oncol; 2023 Dec; 14(6):2536-2548. PubMed ID: 38196538
[TBL] [Abstract][Full Text] [Related]
12. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review.
Long X; Zhang L; Wang WQ; Zhang EL; Lv X; Huang ZY
Onco Targets Ther; 2022; 15():703-716. PubMed ID: 35791424
[TBL] [Abstract][Full Text] [Related]
13. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report.
Liu Z; Fu Z; Li G; Lin D
Onco Targets Ther; 2020; 13():10267-10273. PubMed ID: 33116607
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
[TBL] [Abstract][Full Text] [Related]
15. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Aug; 13(4):1907-1914. PubMed ID: 36092351
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
[TBL] [Abstract][Full Text] [Related]
17. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
Liu K; Wu J; Xu Y; Li D; Huang S; Mao Y
Onco Targets Ther; 2022; 15():1079-1094. PubMed ID: 36212725
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
Front Oncol; 2022; 12():917353. PubMed ID: 36226061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
